Sign up
Pharma Capital

Futura Medical on the rise as Liberum says newspaper article could spark interest in group’s main ED product

Over the weekend The Guardian published an in-depth piece on the emerging treatments for erectile dysfunction (ED) with a significant focus on Futura's MED2005 product
Couple in bed
“This will help to drive interest in what appears to be a very over-looked product in terms of its potential to address a very large market," Liberum's analysts said

Futura Medical PLC (LON:FUM) saw its shares shoot higher on Monday after ‘house’ broker Liberum Capital highlighted an article published in ‘The Guardian’ newspaper which could spark interest in the group’s main product.

In a note to clients, the City broker’s analysts pointed out that over the weekend the newspaper published an in-depth piece on the emerging treatments for erectile dysfunction (ED) with a significant focus on the AIM-listed firm’s MED2005 which is in a P3 study due to read-out by the end of the year.

READ: Futura Medical trial on track to deliver “major value inflection point”

They said: “The article highlights the lack of clinical advances in ED over the past 20 years and the emerging opportunity for products that can address the shortcomings of the PDe-5 inhibitor class (Viagra) with MED2005 appearing to offer convenience and side-effect profile benefits.”

The analysts concluded: “This will help to drive interest in what appears to be a very over-looked product in terms of its potential to address a very large market.”

In afternoon trading, shares in Futura Medical were up 11.6% at 23.15p.

View full FUM profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.